$1.3 Billion Merger Between Akebia Therapeutics and Keryx Biopharmaceuticals to Focus on Kidney Disease

$1.3 Billion Merger Between Akebia Therapeutics and Keryx Biopharmaceuticals to Focus on Kidney Disease

Source: 
CP Wire
snippet: 
  • Combined company will be named Akebia Therapeutics, Inc.
  • Company will focus on patients with chronic kidney disease
  • Combined portfolio can address the needs of an estimated 1.7 million patients in US subject to approval of vadadustat